Tetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor produced by Alhavi Pharmaceutical.
It is used to reduce involuntary (choreiform) movements associated with Huntington’s disease by decreasing dopamine levels in the brain.
Tetrabenazine also helps control tardive dyskinesia caused by prolonged use of antipsychotic medications.
Treatment must be carried out under strict medical supervision, with regular monitoring of neurological and psychiatric side effects.
Tetrabenazine
Dosage form: Tablet
Tetrabenazine is indicated for:
• Treatment of involuntary movements (chorea) associated with Huntington’s disease
• Management of tardive dyskinesia caused by antipsychotic medications
Tetrabenazine works by inhibiting VMAT2, reducing dopamine and serotonin storage in nerve terminals, and decreasing excessive motor activity.
• Initial dose: 12.5–25 mg per day (gradually increased under medical supervision)
• Take with food to minimize gastrointestinal side effects
• Regular monitoring of neurological and psychiatric symptoms is essential
• Do not stop the medication abruptly without consulting your doctor